10-Q: Ovid Therapeutics Reports Third Quarter 2024 Results, Cites Progress in Pipeline Development

Ovid Therapeutics' third quarter 2024 report highlights ongoing research and development efforts, alongside a strategic restructuring to extend its cash runway.

Summary

• Ovid Therapeutics reported a net loss of $14.0 million for the three months ended September 30, 2024, and a net loss of $17.2 million for the nine months ended September 30, 2024.
• The company's cash, cash equivalents, and marketable securities totaled $62.7 million as of September 30, 2024.
• Revenue for the three months ended September 30, 2024, was $173,000, and $490,000 for the nine months ended September 30, 2024, primarily from royalties on net sales.
• Research and development expenses were $7.9 million for the three months ended September 30, 2024, and $30.8 million for the nine months ended September 30, 2024.
• General and administrative expenses were $5.5 million for the three months ended September 30, 2024, and $20.8 million for the nine months ended September 30, 2024.
• The company experienced a $1.8 million loss due to a fraudulent funds transfer.
• A $29.0 million gain was recognized due to an adjustment to the royalty monetization liability.
• Ovid initiated a workforce reduction in June 2024, impacting approximately 43% of its headcount, to prioritize programs and extend its cash runway.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in pipeline development, the financial losses, fraudulent activity, and restructuring efforts indicate significant challenges. The delay in the OV329 trial and the pause in the OV888/GV101 trial are also concerning.

Positives

• The company has $62.7 million in cash, cash equivalents, and marketable securities.
• A $29.0 million gain was recognized due to an adjustment to the royalty monetization liability.
• The company is progressing its pipeline with plans to submit a regulatory application for a Phase 1 trial of OV350 before year end 2024.

Negatives

• Ovid Therapeutics reported a net loss of $14.0 million for the three months ended September 30, 2024, and a net loss of $17.2 million for the nine months ended September 30, 2024.
• The company experienced a $1.8 million loss due to a fraudulent funds transfer.
• The company initiated a workforce reduction in June 2024, impacting approximately 43% of its headcount.
• The company is pausing the initiation of the Phase 2 proof-of-concept study of OV888/GV101 in cerebral cavernous malformations.

Risks

• The company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry.
• The company is highly dependent on its ability to find additional sources of funding.
• The company may not be able to recover the $1.8 million lost due to a fraudulent funds transfer.
• The company's future success is dependent on the successful clinical development, regulatory approval, and commercialization of its drug candidates.
• The company is subject to the risk that Takeda may not progress or may discontinue the development of soticlestat, which would impact potential royalty and milestone payments.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company believes that its existing cash, cash equivalents, and marketable securities will fund its current operating plans through at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. The company expects to submit a regulatory application for a Phase 1 trial of OV350 before year end 2024.

Management Comments

• Management believes that the company's existing cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q.
• Management reassessed certain assumptions for soticlestat that factor into the valuation of the royalty monetization liability and determined the probability of potential commercialization related to Dravet syndrome to be 7.5% and the probability of potential commercialization related to Lennox-Gastaut syndrome to be 0%.

Industry Context

The report reflects the challenges and uncertainties inherent in the biopharmaceutical industry, particularly for companies focused on drug development and clinical trials. The company's strategic restructuring and pipeline adjustments are indicative of the need for adaptability in a competitive and evolving market.

Comparison to Industry Standards

• The company's cash burn rate is typical for a clinical-stage biotech company, but the recent restructuring suggests a move towards greater financial discipline.
• The company's reliance on third-party manufacturers and CROs is standard practice in the industry, but it also introduces risks related to supply chain and clinical trial execution.
• The company's pipeline development strategy, focusing on rare diseases, is a common approach to accelerate clinical trials and regulatory approvals.
• The company's decision to pause the Phase 2 trial of OV888/GV101 after competitor trial results highlights the importance of adapting to new data and market dynamics, a common challenge in the industry.
• The company's loss due to a fraudulent funds transfer is a reminder of the cybersecurity risks faced by all companies, especially those in the pharmaceutical and biotechnology sectors.

Management Changes

Related Party Transactions

• In March 2021, the Company entered into the RLT Agreement with Takeda.

Stakeholder Impact

• Shareholders may be concerned about the company's financial losses and the impact of the restructuring.
• Employees have been affected by the workforce reduction.
• Customers and partners may be impacted by the company's strategic changes and pipeline adjustments.
• Creditors may be concerned about the company's ability to repay debts given the financial losses.

Next Steps

• The company expects to submit a regulatory application for a Phase 1 trial of OV350 before year end 2024.
• The company will evaluate clinical design learnings emerging from competitor Phase 2 programs for OV888/GV101.
• The company will continue to pursue additional formulations of OV888/GV101 for undisclosed cerebral vascular conditions.

Key Dates

Keywords

biopharmaceutical, clinical trials, drug development, neurological disorders, research and development, licensing agreements, financial results, soticlestat, OV329, OV350, OV888/GV101